Gefitinib (Iressa®, AstraZeneca, London, United Kingdom) and erlotinib (Tarceva®, AstraZeneca, London, United Kingdom) are similar drugs that inhibit EGFR in metastatic NSCLC with EGFR-TK activating mutation [3]. Here, EGFR is linked to non-small cell lung carcinoma.